No open-access location is known for this record yet.
No open-access location is known for this record yet.
Amsterdam, the Netherlands—The Second European Stroke Prevention Study, a major clinical trial of a drug to prevent repeat strokes, has become mired in controversy. A paper describing promising results from the trial, published earlier this month, was originally turned down by The Lancet in part because of ethical concerns over the use of placebos, and it has been further tainted by allegations that fabricated data led to the disqualification of information on more than 400 patients.
Loading…
Imported from OpenAlex (CC0) — nothing here is generated.